Fidelity Investments’s UroGen Pharma URGN Stock Holding History

Fidelity Investments’s Portfolio URGN Stock Details URGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$7.25M	Buy	197,098 +52,137	+36%	+$1.41M	﹤0.01%	2266
2026 Q1	$2.61M	Buy	144,961 +21,398	+17%	+$429K	﹤0.01%	2550
2025 Q4	$2.89M	Buy	123,563 +50,447	+69%	+$1.09M	﹤0.01%	2472
2025 Q3	$1.46M	Buy	73,116 +70,726	+2,959%	+$1.27M	﹤0.01%	2659
2025 Q2	$32.7K	Sell	2,390 -510	-18%	-$4.89K	﹤0.01%	4089
2025 Q1	$32.1K	Sell	2,900 -17,071	-85%	-$182K	﹤0.01%	4053
2024 Q4	$213K	Sell	19,971 -3,119	-14%	-$37.3K	﹤0.01%	3244
2024 Q3	$293K	Buy	23,090 +19,670	+575%	+$292K	﹤0.01%	3065
2024 Q2	$57.4K	Buy	3,420 +189	+6%	+$2.69K	﹤0.01%	3547
2024 Q1	$48.5K	Sell	3,231 -1,649	-34%	-$27K	﹤0.01%	3601
2023 Q4	$73.2K	Sell	4,880 -39	-0.8%	-$506	﹤0.01%	3349
2023 Q3	$68.9K	Buy	4,919 +4,416	+878%	+$70.9K	﹤0.01%	3242
2023 Q2	$5.21K	Buy	503 +49	+11%	+$541	﹤0.01%	4354
2023 Q1	$4.2K	Hold	454	–	–	﹤0.01%	4434
2022 Q4	$4.03K	Hold	454	–	–	﹤0.01%	4326
2022 Q3	$4K	Sell	454 -86	-16%	-$711	﹤0.01%	4419
2022 Q2	$4K	Buy	540 +244	+82%	+$1.68K	﹤0.01%	4409
2022 Q1	$3K	Buy	+296	New	+$2.31K	﹤0.01%	4595
2021 Q3	–	Sell	-47,603	Closed	-$727K	–	5057
2021 Q2	$727K	Hold	47,603	–	–	﹤0.01%	2719
2021 Q1	$927K	Hold	47,603	–	–	﹤0.01%	2596
2020 Q4	$858K	Sell	47,603 -12,100	-20%	-$254K	﹤0.01%	2557
2020 Q3	$1.15M	Sell	59,703 -167,800	-74%	-$3.8M	﹤0.01%	2402
2020 Q2	$5.94M	Sell	227,503 -87,100	-28%	-$2.13M	﹤0.01%	1996
2020 Q1	$5.61M	Hold	314,603	–	–	﹤0.01%	1896
2019 Q4	$10.5M	Sell	314,603 -273,600	-47%	-$7.47M	﹤0.01%	1828
2019 Q3	$14M	Hold	588,203	–	–	﹤0.01%	1708
2019 Q2	$21.1M	Hold	588,203	–	–	﹤0.01%	1604
2019 Q1	$21.7M	Buy	588,203 +32,200	+6%	+$1.35M	﹤0.01%	1572
2018 Q4	$23.9M	Hold	556,003	–	–	﹤0.01%	1488
2018 Q3	$26.3M	Sell	556,003 -150,611	-21%	-$7M	﹤0.01%	1569
2018 Q2	$35.2M	Sell	706,614 -157,813	-18%	-$9.18M	﹤0.01%	1457
2018 Q1	$43M	Buy	864,427 +174,597	+25%	+$8.75M	0.01%	1372
2017 Q4	$25.7M	Sell	689,830 -79,400	-10%	-$2.83M	﹤0.01%	1607
2017 Q3	$24.2M	Hold	769,230	–	–	﹤0.01%	1627
2017 Q2	$13.9M	Buy	+769,230	New	+$13.4M	﹤0.01%	1822

Other funds holding URGN

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

JFG

Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return

SG Americas Securities New York $179B AUM 65.34% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

ACA

Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Fidelity Investments's URGN Position: Q2 2026 in Review

Fidelity Investments increased its UroGen Pharma (URGN) stake by 36% in Q2 2026, buying an estimated $1.41M and bringing the position to 197,098 shares worth $7.25M. The position accounts for ﹤0.01% of the portfolio, ranked #2266.

Fidelity Investments first reported a position in URGN in Q2 2017 and has held it in 35 quarters since. The position peaked at $43M in Q1 2018. 189 funds tracked by Wall St. Rank hold URGN as of Q2 2026.

Fidelity Investments held 197,098 shares of UroGen Pharma worth $7.25M as of Q2 2026.
Fidelity Investments bought 52,137 UroGen Pharma shares in Q2 2026, an estimated $1.41M.
UroGen Pharma made up ﹤0.01% of Fidelity Investments's portfolio in Q2 2026, its #2266 holding.
Fidelity Investments first reported a position in UroGen Pharma in Q2 2017 and has held it in 35 quarters since.
Fidelity Investments's UroGen Pharma position peaked at $43M in Q1 2018.
189 funds tracked by Wall St. Rank held UroGen Pharma as of Q2 2026.

Based on Fidelity Investments's 13F filing for Q2 2026, filed 13 Aug 2026.